Onsdag 30 Oktober | 09:27:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2026-01-28 08:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-17 08:00 Kvartalsrapport 2025-Q2
2025-05-06 - Årsstämma
2025-04-23 08:00 Kvartalsrapport 2025-Q1
2025-01-28 08:00 Bokslutskommuniké 2024
2024-10-22 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning PROB 1.30 SEK
2024-05-07 - Årsstämma
2024-04-23 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning PROB 1.30 SEK
2023-05-04 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-21 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning PROB 1.30 SEK
2022-05-05 - Årsstämma
2022-04-26 - Kvartalsrapport 2022-Q1
2022-02-02 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-07-26 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning PROB 1.10 SEK
2021-05-07 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-09 - Bokslutskommuniké 2020
2020-10-21 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning PROB 1.00 SEK
2020-05-13 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-07-19 - Kvartalsrapport 2019-Q2
2019-05-08 - X-dag ordinarie utdelning PROB 0.00 SEK
2019-05-07 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-08-13 - Kvartalsrapport 2018-Q2
2018-05-03 - X-dag ordinarie utdelning PROB 0.00 SEK
2018-05-02 - Årsstämma
2018-05-02 - Kvartalsrapport 2018-Q1
2018-01-25 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-05 - X-dag ordinarie utdelning PROB 1.00 SEK
2017-05-04 - Kvartalsrapport 2017-Q1
2017-01-24 - Bokslutskommuniké 2016
2016-10-18 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-06-29 - Extra Bolagsstämma 2016
2016-04-28 - X-dag ordinarie utdelning PROB 1.00 SEK
2016-04-27 - Kvartalsrapport 2016-Q1
2016-04-27 - Årsstämma
2016-01-26 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-07-16 - Kvartalsrapport 2015-Q2
2015-04-24 - X-dag ordinarie utdelning PROB 0.85 SEK
2015-04-23 - Årsstämma
2015-04-23 - Kvartalsrapport 2015-Q1
2015-01-28 - Bokslutskommuniké 2014
2014-10-29 - Analytiker möte 2014
2014-10-29 - Kvartalsrapport 2014-Q3
2014-08-19 - Kvartalsrapport 2014-Q2
2014-04-30 - X-dag ordinarie utdelning PROB 0.75 SEK
2014-04-29 - Kvartalsrapport 2014-Q1
2014-04-29 - Årsstämma
2014-01-23 - Bokslutskommuniké 2013
2013-10-22 - Kvartalsrapport 2013-Q3
2013-08-20 - Kvartalsrapport 2013-Q2
2013-04-25 - X-dag ordinarie utdelning PROB 0.75 SEK
2013-04-24 - Årsstämma
2013-04-24 - Kvartalsrapport 2013-Q1
2013-01-24 - Bokslutskommuniké 2012
2012-10-18 - Kvartalsrapport 2012-Q3
2012-09-28 - Kapitalmarknadsdag 2012
2012-08-16 - Kvartalsrapport 2012-Q2
2012-04-26 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-01-25 - Bokslutskommuniké 2011
2011-10-19 - Kvartalsrapport 2011-Q3
2011-07-19 - Kvartalsrapport 2011-Q2
2011-04-29 - X-dag bonusutdelning PROB 0.5
2011-04-29 - X-dag ordinarie utdelning PROB 0.50 SEK
2011-04-28 - Årsstämma
2011-04-28 - Kvartalsrapport 2011-Q1
2011-01-26 - Bokslutskommuniké 2010
2010-10-20 - Kvartalsrapport 2010-Q3
2010-07-20 - Kvartalsrapport 2010-Q2
2010-04-23 - X-dag ordinarie utdelning PROB 0.50 SEK
2010-04-22 - Årsstämma
2010-04-22 - Kvartalsrapport 2010-Q1
2010-01-27 - Bokslutskommuniké 2009
2009-10-21 - Kvartalsrapport 2009-Q3
2009-08-18 - Kvartalsrapport 2009-Q2
2009-05-07 - X-dag ordinarie utdelning PROB 0.00 SEK
2009-05-06 - Årsstämma
2009-04-22 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Probi är verksamt inom bioteknik. Bolaget är särskilt inriktade mot forskning och utveckling av probiotika, en god bakterie som återfinns i människans tarmsystem. Forskningsområdena inom bolaget innefattar mag och tarm, immunförsvar, metabola syndrom samt stress och återhämtning. Bland bolagets kunder återfinns större företagskunder inom livsmedelsindustrin. Bolaget grundades under 1991 och har sitt huvudkontor i Lund.
2023-10-19 13:15:00

To assist our customers and partners in capitalizing on the fast-expanding synbiotic market, valued at USD 1.3 billion by 2027[1], Probi and Clasado Biosciences (`Clasado') will launch two new scientifically proven synbiotic formulations.

There is a rising interest and awareness in health and nutrition, where consumers seek ways to improve digestive, immune, and overall health.[1] High consumer awareness together with prevalent marketing are the major factors driving the demand for synbiotic products, as the growing health consciousness among consumers is expected to drive market growth in synbiotics, with a projected annual growth rate of 8.3% from 2020 to 2027 globally.[2]

At this year's Supply Side West, in Las Vegas, Probi and Clasado will launch two new synbiotic solutions:
  • Bimuno[®] GOS and Probi Defendum[® ]which demonstrate a clear synergistic synbiotic combination as the probiotic strains in Probi Defendum selectively utilize the prebiotic GOS to enhance the production of short chain fatty acids.
  • Bimuno[®] GOS and Probi Digestis[® ]that showcases complementary mechanisms of action and enter the market as the most researched synbiotic ingredient pairing, with extensive studies behind both ingredients covering almost 340 publications between them.

"In today's health and wellness market, consumers seek scientifically backed products that they can trust, and our collaborative launch with Clasado positions us in the forefront of the growing synbiotic market, based on research and empirical evidence. Probi Digestis and Probi Defendum are extensively studied probiotic concepts, and we look forward to advancing the wider synbiotic category with our evidence-based approach", says Anita Johansen CEO of Probi.

"The biotics category is experiencing an unprecedented era of growth and discovery, and we are thrilled to reveal our synbiotic combinations in partnership with Probi, at SupplySide West. By synergizing our expertise, we are taking the guesswork away for formulators with predetermined and scientifically backed combinations, based on the most comprehensively studied ingredients of their kind. This unlocks faster speed to market, as well as more reliable results", says Per Rehné, CEO of Clasado.

To uncover the benefits of the concepts, you are welcome to visit Probi at booth #5851, and Clasado at booth #5605, during SupplySide West, 25[th] - 26[th] of October.

Synbiotic Fast Facts

Synbiotic's is defined as "a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host".[3] Furthermore, a synbiotic solution can be either synergistic or complementary. A synergistic synbiotic is a solution where "the substrate is designed to be selectively utilized by the co-administered microorganism(s)"[3], in this case the solution is composed of a prebiotic and a probiotic that selectively nourish each other and results in a stronger health benefit in the host, than what can be seen by one of the ingredients alone. "A complementary synbiotic is a synbiotic composed of a probiotic combined with a prebiotic, which is designed to target autochthonous microorganisms".[3] in this case defined as a prebiotic and probiotic working side by side, each of them delivering their proposed health benefit to the host. According to the definitions by ISAPP[3 ]it is required that both the prebiotic and the probiotic must meet the minimal requirements defined for each component.

[1 ]FMI Synbiotics products market June 2022

[2] Synbiotic Product Market Size | Industry Growth Report, 2027 (grandviewresearch.com) (https://www.grandviewresearch.com/industry-analysis/synbiotic-product-market)

[2] International Scientific Association for Probiotics and Prebiotics (ISAPP)

For further information, please contact:

Anita Johansen, CEO, Probi, Phone: +46 46 286 89 48, E-mail: anita.johansen@probi.com
Christina Vegge, Senior Director R&D, Probi, Phone +46 733 00 43 56, E-mail: christina.vegge@probi.com

ABOUT PROBI

Probi[®] is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.